Longitudinal changes in LIC and other parameters in patients receiving different chelation regimens: Data from LICNET

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|100|2|124-130

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.100, Iss.2, 2018-02, pp. : 124-130

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Real‐life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 361-370

John Wiley & Sons Inc

Access to resources Recommend Favorite

Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-02 ,pp. : 148-152

Karger

Access to resources Recommend Favorite

Immune Status of Thalassemic Patients Receiving Deferiprone or Combined Deferiprone and Desferrioxamine Chelation Treatment

By  

Acta Haematologica, Vol. 110, Iss. 4, 2003-12 ,pp. : 224-226

Karger

Access to resources Recommend Favorite

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

By  

AMERICAN JOURNAL OF TRANSPLANTATION, Vol. 15, Iss. 7, 2015-07 ,pp. : 1843-1854

John Wiley & Sons Inc

Access to resources Recommend Favorite

LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 330-335

John Wiley & Sons Inc

Access to resources Recommend Favorite